Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Siegfried Janz MD

Siegfried Janz MD

Professor

Institution: Medical College of Wisconsin
Department: Medicine
Division: Hematology and Oncology - Medicine
Program: Bone Marrow Transplant

Member of the Cancer Center


Publications

  • New wrinkle on deubiquitination in B-cell lymphoma. (Janz S) Blood 2018 Dec 13;132(24):2529-2530 PMID: 30545891 12/14/2018    
  • Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma. (Gu C, Jing X, Holman C, Sompallae R, Zhan F, Tricot G, Yang Y, Janz S) BMC Cancer 2018 Nov 21;18(1):1152 PMID: 30463534 PMCID: PMC6249818 11/23/2018    
  • Upregulation of FOXM1 in a subset of relapsed myeloma results in poor outcome. (Gu C, Holman C, Sompallae R, Jing X, Tomasson M, Hose D, Seckinger A, Zhan F, Tricot G, Goldschmidt H, Yang Y, Janz S) Blood Cancer J 2018 02 15;8(2):22 PMID: 29449574 PMCID: PMC5814454 02/17/2018       2 Citations
  • Chromosomal instability and acquired drug resistance in multiple myeloma. (Wang W, Zhang Y, Chen R, Tian Z, Zhai Y, Janz S, Gu C, Yang Y) Oncotarget 2017 Sep 29;8(44):78234-78244 PMID: 29100463 PMCID: PMC5652852 11/05/2017    
  • NEK2 induces osteoclast differentiation and bone destruction via heparanase in multiple myeloma. (Hao M, Franqui-Machin R, Xu H, Shaughnessy J Jr, Barlogie B, Roodman D, Quelle DE, Janz S, Tomasson MH, Sanderson RD, Qiu L, Frech I, Tricot G, Zhan F) Leukemia 2017 07;31(7):1648-1650 PMID: 28400617 PMCID: PMC5508075 04/13/2017       4 Citations
  • Transgenic mouse model of IgM lymphoproliferative disease mimicking Waldenström macroglobulinemia. (Tompkins VS, Sompallae R, Rosean TR, Walsh S, Acevedo M, Kovalchuk AL, Han SS, Jing X, Holman C, Rehg JE, Herms S, Sunderland JS, Morse HC, Janz S) Blood Cancer J 2016 11 04;6(11):e488 PMID: 27813533 PMCID: PMC5148059 11/05/2016       1 Citations
  • Mouse model of MYD88L265P-dependent DLBCL. (Janz S) Blood 2016 06 02;127(22):2660-1 PMID: 27257177 06/04/2016    
  • PIAS1 Promotes Lymphomagenesis through MYC Upregulation. (Rabellino A, Melegari M, Tompkins VS, Chen W, Van Ness BG, Teruya-Feldstein J, Conacci-Sorrell M, Janz S, Scaglioni PP) Cell Rep 2016 06 07;15(10):2266-2278 PMID: 27239040 PMCID: PMC4899214 05/31/2016       3 Citations
  • KSHV-encoded vIL-6 collaborates with deregulated c-Myc to drive plasmablastic neoplasms in mice. (Rosean TR, Holman CJ, Tompkins VS, Jing X, Krasowski MD, Rose-John S, Janz S) Blood Cancer J 2016 Feb 26;6:e398 PMID: 26918362 PMCID: PMC4771969 02/27/2016       6 Citations
  • FOXM1 is a therapeutic target for high-risk multiple myeloma. (Gu C, Yang Y, Sompallae R, Xu H, Tompkins VS, Holman C, Hose D, Goldschmidt H, Tricot G, Zhan F, Janz S) Leukemia 2016 Apr;30(4):873-82 PMID: 26648534 PMCID: PMC4826574 12/10/2015       13 Citations
  • Cancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction? (Franqui-Machin R, Wendlandt EB, Janz S, Zhan F, Tricot G) Oncotarget 2015 Dec 01;6(38):40496-506 PMID: 26415231 PMCID: PMC4747348 09/29/2015       22 Citations
  • Adoptive B-cell transfer mouse model of human myeloma. (Tompkins VS, Rosean TR, Holman CJ, DeHoedt C, Olivier AK, Duncan KM, Jing X, Foor SD, Acevedo MR, Walsh SA, Tricot G, Zhan F, Janz S) Leukemia 2016 Apr;30(4):962-6 PMID: 26202932 PMCID: PMC4821809 07/24/2015       2 Citations
  • RIP1 Cleavage in the Kinase Domain Regulates TRAIL-Induced NF-κB Activation and Lymphoma Survival. (Zhang L, Blackwell K, Workman LM, Chen S, Pope MR, Janz S, Habelhah H) Mol Cell Biol 2015 Oct;35(19):3324-38 PMID: 26195820 PMCID: PMC4561725 07/22/2015       7 Citations
  • CDKN1A and FANCD2 are potential oncotargets in Burkitt lymphoma and multiple myeloma. (Han SS, Tompkins VS, Son DJ, Han S, Yun H, Kamberos NL, Dehoedt CL, Gu C, Holman C, Tricot G, Zhan F, Janz S) Exp Hematol Oncol 2015;4:9 PMID: 25838973 PMCID: PMC4383050 04/04/2015    
  • Bruton tyrosine kinase is a therapeutic target in stem-like cells from multiple myeloma. (Yang Y, Shi J, Gu Z, Salama ME, Das S, Wendlandt E, Xu H, Huang J, Tao Y, Hao M, Franqui R, Levasseur D, Janz S, Tricot G, Zhan F) Cancer Res 2015 Feb 01;75(3):594-604 PMID: 25589346 PMCID: PMC4384656 01/16/2015       29 Citations
  • NIAM-deficient mice are predisposed to the development of proliferative lesions including B-cell lymphomas. (Reed SM, Hagen J, Muniz VP, Rosean TR, Borcherding N, Sciegienka S, Goeken JA, Naumann PW, Zhang W, Tompkins VS, Janz S, Meyerholz DK, Quelle DE) PLoS One 2014;9(11):e112126 PMID: 25393878 PMCID: PMC4231569 11/14/2014       5 Citations
  • The tumor microenvironment is the main source of IL-6 for plasma cell tumor development in mice. (Rosean TR, Tompkins VS, Olivier AK, Sompallae R, Norian LA, Morse HC 3rd, Waldschmidt TJ, Janz S) Leukemia 2015 Jan;29(1):233-7 PMID: 25257990 PMCID: PMC4286499 09/27/2014       11 Citations
  • NEK2 mediates ALDH1A1-dependent drug resistance in multiple myeloma. (Yang Y, Zhou W, Xia J, Gu Z, Wendlandt E, Zhan X, Janz S, Tricot G, Zhan F) Oncotarget 2014 Dec 15;5(23):11986-97 PMID: 25230277 PMCID: PMC4322982 09/18/2014       18 Citations
  • Forkhead box M1 regulates quiescence-associated radioresistance of human head and neck squamous carcinoma cells. (Eckers JC, Kalen AL, Sarsour EH, Tompkins VS, Janz S, Son JM, Doskey CM, Buettner GR, Goswami PC) Radiat Res 2014 Oct;182(4):420-9 PMID: 25229973 PMCID: PMC4221113 09/18/2014       5 Citations
  • Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. (Rosean TR, Tompkins VS, Tricot G, Holman CJ, Olivier AK, Zhan F, Janz S) Immunol Res 2014 Aug;59(1-3):188-202 PMID: 24845460 PMCID: PMC4209159 05/23/2014       15 Citations
  • A new model of LMP1-MYC interaction in B cell lymphoma. (Ontiveros EP, Halwani A, Stunz LL, Kamberos N, Olivier AK, Janz S, Bishop GA) Leuk Lymphoma 2014 Dec;55(12):2917-23 PMID: 24605938 PMCID: PMC4207734 03/13/2014       2 Citations
  • ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signatures in multiple myeloma. (Zhou W, Yang Y, Gu Z, Wang H, Xia J, Wu X, Zhan X, Levasseur D, Zhou Y, Janz S, Tricot G, Shi J, Zhan F) Leukemia 2014 May;28(5):1155-8 PMID: 24365790 PMCID: PMC4018236 12/25/2013       26 Citations
  • (18)F-FDG-PET/CT imaging in an IL-6- and MYC-driven mouse model of human multiple myeloma affords objective evaluation of plasma cell tumor progression and therapeutic response to the proteasome inhibitor ixazomib. (Duncan K, Rosean TR, Tompkins VS, Olivier A, Sompallae R, Zhan F, Tricot G, Acevedo MR, Ponto LL, Walsh SA, Tygrett LT, Berger AJ, Waldschmidt T, Morse HC 3rd, Sunderland JJ, Janz S) Blood Cancer J 2013 Nov 29;3:e165 PMID: 24292417 PMCID: PMC3880444 12/03/2013    
  • Identification of candidate B-lymphoma genes by cross-species gene expression profiling. (Tompkins VS, Han SS, Olivier A, Syrbu S, Bair T, Button A, Jacobus L, Wang Z, Lifton S, Raychaudhuri P, Morse HC 3rd, Weiner G, Link B, Smith BJ, Janz S) PLoS One 2013;8(10):e76889 PMID: 24130802 PMCID: PMC3793908 10/17/2013       4 Citations
  • Waldenström macroglobulinemia: clinical and immunological aspects, natural history, cell of origin, and emerging mouse models. (Janz S) ISRN Hematol 2013 Sep 09;2013:815325 PMID: 24106612 PMCID: PMC3782845 10/10/2013    
  • Piperlongumine inhibits LMP1/MYC-dependent mouse B-lymphoma cells. (Han SS, Tompkins VS, Son DJ, Kamberos NL, Stunz LL, Halwani A, Bishop GA, Janz S) Biochem Biophys Res Commun 2013 Jul 12;436(4):660-5 PMID: 23764397 PMCID: PMC3749779 06/15/2013       16 Citations
  • Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib. (Stessman HA, Mansoor A, Zhan F, Janz S, Linden MA, Baughn LB, Van Ness B) Leukemia 2013 Oct;27(10):2075-7 PMID: 23728080 PMCID: PMC4053943 06/04/2013       24 Citations
  • Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model. (Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG) Mol Cancer Ther 2013 Jun;12(6):1140-50 PMID: 23536725 PMCID: PMC4076840 03/29/2013       35 Citations
  • Piperlongumine inhibits proliferation and survival of Burkitt lymphoma in vitro. (Han SS, Son DJ, Yun H, Kamberos NL, Janz S) Leuk Res 2013 Feb;37(2):146-54 PMID: 23237561 PMCID: PMC3551475 12/15/2012       29 Citations
  • The feed-forward loop between YB-1 and MYC is essential for multiple myeloma cell survival. (Bommert KS, Effenberger M, Leich E, Küspert M, Murphy D, Langer C, Moll R, Janz S, Mottok A, Weissbach S, Rosenwald A, Bargou R, Bommert K) Leukemia 2013 Feb;27(2):441-50 PMID: 22772059 PMCID: PMC4047128 07/10/2012       12 Citations
  • Characterization of ARF-BP1/HUWE1 interactions with CTCF, MYC, ARF and p53 in MYC-driven B cell neoplasms. (Qi CF, Kim YS, Xiang S, Abdullaev Z, Torrey TA, Janz S, Kovalchuk AL, Sun J, Chen D, Cho WC, Gu W, Morse HC 3rd) Int J Mol Sci 2012;13(5):6204-19 PMID: 22754359 PMCID: PMC3382761 07/04/2012       11 Citations
  • HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. (Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, Rosean TR, Klapper W, Tosato G, Janz S, Scheller J, Rose-John S) Blood 2012 May 31;119(22):5173-81 PMID: 22490805 PMCID: PMC3370672 04/12/2012       67 Citations
  • Global gene expression profiling in mouse plasma cell tumor precursor and bystander cells reveals potential intervention targets for plasma cell neoplasia. (LeGrand J, Park ES, Wang H, Gupta S, Owens JD Jr, Nelson PJ, DuBois W, Bair T, Janz S, Mushinski JF) Blood 2012 Jan 26;119(4):1018-28 PMID: 22147894 PMCID: PMC3271714 12/08/2011       5 Citations
  • Antitumor activity of the investigational proteasome inhibitor MLN9708 in mouse models of B-cell and plasma cell malignancies. (Lee EC, Fitzgerald M, Bannerman B, Donelan J, Bano K, Terkelsen J, Bradley DP, Subakan O, Silva MD, Liu R, Pickard M, Li Z, Tayber O, Li P, Hales P, Carsillo M, Neppalli VT, Berger AJ, Kupperman E, Manfredi M, Bolen JB, Van Ness B, Janz S) Clin Cancer Res 2011 Dec 01;17(23):7313-23 PMID: 21903769 PMCID: PMC3443972 09/10/2011       66 Citations
  • B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. (Zhang W, Kater AP, Widhopf GF 2nd, Chuang HY, Enzler T, James DF, Poustovoitov M, Tseng PH, Janz S, Hoh C, Herschman H, Karin M, Kipps TJ) Proc Natl Acad Sci U S A 2010 Nov 02;107(44):18956-60 PMID: 20956327 PMCID: PMC2973856 10/20/2010       43 Citations
  • Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia. (de Jong D, Janz S) J Pathol 2010 Jul;221(3):242-7 PMID: 20527018 PMCID: PMC3118561 06/09/2010    
  • Genetic reporter system for oncogenic Igh-Myc translocations in mice. (Takizawa M, Kim JS, Tessarollo L, McNeil N, Waldschmidt TJ, Casellas R, Ried T, Janz S) Oncogene 2010 Jul 15;29(28):4113-20 PMID: 20453890 PMCID: PMC3108853 05/11/2010       1 Citations
  • NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. (Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S) Mol Cancer 2010 Apr 30;9:97 PMID: 20433747 PMCID: PMC2876994 05/04/2010       70 Citations
  • Ectopic expression of wild-type FGFR3 cooperates with MYC to accelerate development of B-cell lineage neoplasms. (Zingone A, Cultraro CM, Shin DM, Bean CM, Morse HC 3rd, Janz S, Kuehl WM) Leukemia 2010 Jun;24(6):1171-8 PMID: 20393505 PMCID: PMC3118571 04/16/2010       12 Citations
  • IL-6 and MYC collaborate in plasma cell tumor formation in mice. (Rutsch S, Neppalli VT, Shin DM, DuBois W, Morse HC 3rd, Goldschmidt H, Janz S) Blood 2010 Mar 04;115(9):1746-54 PMID: 20018915 PMCID: PMC2832814 12/19/2009       35 Citations
  • Prevalence and frequency of circulating t(14;18)-MBR translocation carrying cells in healthy individuals. (Schüler F, Dölken L, Hirt C, Kiefer T, Berg T, Fusch G, Weitmann K, Hoffmann W, Fusch C, Janz S, Rabkin CS, Dölken G) Int J Cancer 2009 Feb 15;124(4):958-63 PMID: 19030176 PMCID: PMC4216731 11/26/2008       58 Citations
  • Deregulation of c-Myc Confers distinct survival requirements for memory B cells, plasma cells, and their progenitors. (Khuda SE, Loo WM, Janz S, Van Ness B, Erickson LD) J Immunol 2008 Dec 01;181(11):7537-49 PMID: 19017943 PMCID: PMC2841033 11/20/2008       19 Citations
  • Mechanisms and consequences of chromosomal translocation. (Rabkin CS, Janz S) Cancer Epidemiol Biomarkers Prev 2008 Aug;17(8):1849-51 PMID: 18708370 PMCID: PMC2562255 08/19/2008       1 Citations
  • Overview of mechanisms and consequences of chromosomal translocation. (Rabkin CS, Janz S) J Natl Cancer Inst Monogr 2008(39):1 PMID: 18647992 07/24/2008    
  • t(14;18) Translocations and risk of follicular lymphoma. (Rabkin CS, Hirt C, Janz S, Dölken G) J Natl Cancer Inst Monogr 2008(39):48-51 PMID: 18648003 07/24/2008       19 Citations
  • Genetic and environmental cofactors of Myc translocations in plasma cell tumor development in mice. (Janz S) J Natl Cancer Inst Monogr 2008(39):37-40 PMID: 18648000 07/24/2008       5 Citations
  • AID-deficient Bcl-xL transgenic mice develop delayed atypical plasma cell tumors with unusual Ig/Myc chromosomal rearrangements. (Kovalchuk AL, duBois W, Mushinski E, McNeil NE, Hirt C, Qi CF, Li Z, Janz S, Honjo T, Muramatsu M, Ried T, Behrens T, Potter M) J Exp Med 2007 Nov 26;204(12):2989-3001 PMID: 17998390 PMCID: PMC2118515 11/14/2007       37 Citations
  • Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. (Fujita K, Janz S) Mol Cancer 2007 Oct 30;6:71 PMID: 17971207 PMCID: PMC2173906 11/01/2007       114 Citations
  • Gene expression profiling reveals different pathways related to Abl and other genes that cooperate with c-Myc in a model of plasma cell neoplasia. (Park ES, Shaughnessy JD Jr, Gupta S, Wang H, Lee JS, Woo HG, Zhan F, Owens JD Jr, Potter M, Janz S, Mushinski JF) BMC Genomics 2007 Aug 31;8:302 PMID: 17764563 PMCID: PMC2040348 09/04/2007       19 Citations
  • Last update: 01/23/2019
    jenkins-FCD Prod-321 98992d628744e349846c2f62ac68f241d7e1ea70